Dehydroepiandrosterone-mediated decrease in caloric intake by obese Zucker rats is not due to changes in serum...

Area of Science:

• Endocrinology
• Neuroscience
• Metabolic Research

Background:

• Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone with known effects on appetite.
• Enterostatin (E), a pentapeptide, selectively reduces fat intake and is implicated in appetite modulation.
• Understanding DHEA's mechanism in appetite control requires examining its impact on key neuropeptides like enterostatin.

Purpose of the Study:

• To investigate the effect of DHEA administration on serum levels of enterostatin (E) in lean and obese Zucker rats.
• To determine if changes in body weight or caloric intake mediate the effect of DHEA on enterostatin levels.
• To explore whether DHEA influences enterostatin peptide metabolism.

Main Methods:

• Lean and obese Zucker rats were treated with DHEA (0.6% in chow) for 16 weeks.
• A pair-fed group of obese rats controlled for caloric intake effects.
• Serum enterostatin-like immunoreactivity (E-LI) was measured using ELISA; peptide metabolism was assessed by disappearance rate.

Main Results:

• DHEA treatment significantly reduced circulating E-LI in both lean and obese rats compared to controls.
• Serum E-LI levels were lower in DHEA-treated obese rats than pair-fed controls, though not statistically significant.
• DHEA treatment did not increase peptide metabolism; instead, it appeared to attenuate it, contrary to initial hypotheses.

Conclusions:

• DHEA administration effectively lowers serum enterostatin levels in both lean and obese Zucker rats.
• The observed decrease in enterostatin is not a secondary effect of DHEA-induced changes in body weight, caloric intake, or peptide metabolism.
• DHEA is a potent modulator of enterostatin levels, but its precise role in appetite regulation via this mechanism requires further investigation.